articles

Reading The Retina: Predicting Diabetic Retinopathy Progression Through Biomarkers 

Janelle Sigala

Diabetic retinopathy is one of the most common complications of diabetes and is a leading cause of vision loss among many working age adults by their mid 30s. This is a worldwide issue as it develops when prolonged high blood sugar damages the tiny blood vessels located in the retina, causing them to weaken, or close off entirely. If left unmanaged, this damage can progress silently for years on end before a person notices any change in their sight, by which treatment at that point becomes far more limited. 

For decades, monitoring diabetic retinopathy has relied heavily on periodic eye exams that capture just a single snapshot in time. But researchers are increasingly turning toward a more predictive approach; using retinal biomarkers to estimate not just when a patient has this disease, but also how quickly it is likely to worsen if left untreated. 

What are Retinal Biomarkers? 

Retinal biomarkers are able to be measured, visible changes within the eye that reflect the underlying health of its blood vessels and tissue, things like hemorrhages, and abnormal vessel growth. Now many are treating these findings as a source to indicate an underlying presence of this disease, researchers are studying them as early indicators that can be tracked over time to recognize the trajectory of the disease.

This matters because diabetic retinopathy does not progress at the same rate in every patient. Some may experience slow and gradual changes, while others move toward vision threatening stages at a rapid rate. Biomarkers are able to offer a way to distinguish between these paths before irreversible damage occurs, rather than relying solely on symptoms that are visible at a yearly optometry visit. 

Why Early Prediction Matters

One of the most challenging aspects of this disease is that vision loss often occurs only after significant damage has already taken place. With this in mind patients may conclude that when blurred vision is reported, the disease may have advanced well beyond its earliest, and most treatable stages. 

Predicting progression through biomarkers would allow clinicians to identify high risk patients much earlier, even while vision still appears largely unaffected. This has opened the door to intervention that can take place to closely monitor, adjust treatment, or an earlier intervention from their provider. All of which can change the outcome for a patient who might otherwise progress toward severe vision loss undetected. 

Why This Research Matters 

This research holds a large significance not only for Ophthalmologists and clinicians, but for the millions of people who suffer with diabetes worldwide who face an elevated risk of vision complications. As diagnostic tools progress beyond simple detection and toward actual prediction, there is an evolving potential to be able to catch diabetic retinopathy at its most treatable stage, before biomarkers become symptoms, and before symptoms become permanent loss occurs for the 100 million adults worldwide.